Ogawa Yoshiyuki, Yanagisawa Kunio, Ishizaki Takuma, Shimizu Hiroaki, Mitsui Takeki, Ichinose Akitada, Nojima Yoshihisa, Handa Hiroshi
Department of Medicine and Clinical Science, Gunma University Graduate School of Medicine.
Rinsho Ketsueki. 2017;58(1):42-46. doi: 10.11406/rinketsu.58.42.
Autoimmune thrombotic and hemostatic disorders, caused by autoantibodies against various factors regulating thrombosis and hemostasis, are rare. Rituximab (RTX) is on occasion used for treating these disorders. Late-onset neutropenia (LON) has been described as a side effect of RTX treatment for patients with hemato-oncological and/or rheumatological diseases but not for those with autoimmune thrombotic and hemostatic disorders. Eleven patients with autoimmune thrombotic and hemostatic disorders received RTX in our institution. Four of these 11 cases (36.4%) developed LON after a median 72.6 days of RTX administration (range 43-122). Three cases required G-CSF, but no severe infections developed.
由针对各种调节血栓形成和止血的因子的自身抗体引起的自身免疫性血栓形成和止血障碍很罕见。利妥昔单抗（RTX）偶尔用于治疗这些疾病。迟发性中性粒细胞减少症（LON）已被描述为RTX治疗血液肿瘤和/或风湿性疾病患者的副作用，但在自身免疫性血栓形成和止血障碍患者中并非如此。我们机构中有11例自身免疫性血栓形成和止血障碍患者接受了RTX治疗。这11例中的4例（36.4%）在RTX给药中位72.6天（范围43 - 122天）后发生了LON。3例需要使用粒细胞集落刺激因子（G-CSF），但未发生严重感染。
